Skip to content
Register Sign in Wishlist

Progress in Neurotherapeutics and Neuropsychopharmacology

Volume 3. 2008

$43.99 (G)

Jeffrey L. Cummings, Antonio Culebras, Javier Borja, Julián García-Rafanell, Andrew D. Barreto, James C. Grotta, Sven E. Pålhagen, Esa Heinonen, Kelly E. Lyons, Rajesh Pahwa, G. Stennis Watson, Suzanne Craft, P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong, D. Garceau, E. Cittadini, P. J. Goadsby, Daniel Wynn, Catherine Meyer, Neil Allen, Dennis O'Brien, George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink, Roberta Tankanow, Robert B. Dick, Julia Sitterly, Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma, James P. Young, Hossein A. Khalili, Kamyar Keramatian, Erik Hessen, Morten I. Lossius, Ivar Reinvang, Leif Gjerstad, Paul B. Fitzgerald, F. Van Nieuwerburgh, D. Deforce, D. A. J. P. Denys, John P. O'Reardon, Karen E. Groff, Albert J. Stunkard, Kelly C. Allison, John H. Peloian, Joseph M. Pierre, Guochuan Emil Tsai
View all contributors
  • Date Published: August 2009
  • availability: Available
  • format: Paperback
  • isbn: 9780521115612

$ 43.99 (G)
Paperback

Add to cart Add to wishlist

Other available formats:
Hardback, eBook


Looking for an examination copy?

If you are interested in the title for your course we can consider offering an examination copy. To register your interest please contact collegesales@cambridge.org providing details of the course you are teaching.

Description
Product filter button
Description
Contents
Resources
Courses
About the Authors
  • Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practicing neurologists as well as clinical and translational neuroscientists.

    • Annual update on clinical trials in neurotherapeutics and psychopharmacology
    • Editor, editorial board and contributors are all leading international figures
    • Provides the evidence on which to base treatments
    • Essential resource for clinicians and neuroscientists
    Read more

    Reviews & endorsements

    'Of interest to adult neurologists and psychiatrists.' Pediatric Endocrinology Reviews

    Customer reviews

    Not yet reviewed

    Be the first to review

    Review was not posted due to profanity

    ×

    , create a review

    (If you're not , sign out)

    Please enter the right captcha value
    Please enter a star rating.
    Your review must be a minimum of 12 words.

    How do you rate this item?

    ×

    Product details

    • Date Published: August 2009
    • format: Paperback
    • isbn: 9780521115612
    • length: 312 pages
    • dimensions: 244 x 17 x 170 mm
    • weight: 0.5kg
    • availability: Available
  • Table of Contents

    Contributors
    1. Progress in neurotherapeutics and neuropsychopharmacology Jeffrey L. Cummings
    2. Trifusal versus aspirin for the prevention of stroke Antonio Culebras, Javier Borja and Julián García-Rafanell
    3. The Argatroban and tPA stroke study Andrew D. Barreto and James C. Grotta
    4. Use of Selegiline as monotherapy and in combination with Levodopa in the management of Parkinson's disease: perspectives from the MONOCOMB study Sven E. Pålhagen and Esa Heinonen
    5. Ropinirole 24-h prolonged release in advanced Parkinson's disease: review of a randomised, double-blind, placebo-controlled study (EASE PD - adjunct study) Kelly E. Lyons and Rajesh Pahwa
    6. Insulin resistance and Alzheimer's disease: pathophysiology and treatment G. Stennis Watson and Suzanne Craft
    7. Targeting Amyloid with Tramiprosate in patients with mild-to-moderate Alzheimer's disease P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong and D. Garceau
    8. Intranasal Zolmitriptan is effective and well-tolerated in acute cluster headache: a randomized placebo-controlled double-blind crossover study E. Cittadini and P. J. Goadsby
    9. Optimal dosing of immunomodulating drugs: a dose-comparison study of GA in RRMS Daniel Wynn, Catherine Meyer, Neil Allen and Dennis O'Brien
    10. Tetrathiomolybdate versus Trientine in the initial treatment of neurologic Wilson's disease George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink, Roberta Tankanow, Robert B. Dick and Julia Sitterly
    11. Randomized clinical trials of Pregabalin for neuropathic pain: methods, results, and implications Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma and James P. Young
    12. Effect of Methylphenidate in patients with acute traumatic brain injury: a randomized clinical trial Hossein A. Khalili and Kamyar Keramatian
    13. Improvement in speeded cognitive processing after anti-epileptic drug withdrawal - a controlled study in mono-therapy patients Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad
    14. A randomized-controlled trial of bilateral rTMS for treatment-resistant depression Paul B. Fitzgerald
    15. Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder F. Van Nieuwerburgh, D. Deforce and D. A. J. P. Denys
    16. Night eating syndrome and results from the first placebo-controlled trial of treatment, with the SSRI medication, Sertraline: implications for clinical practice John P. O'Reardon Karen E. Groff, Albert J. Stunkard and Kelly C. Allison
    17. Modafinil: a candidate for pharmacotherapy of negative symptoms in schizophrenia John H. Peloian and Joseph M. Pierre
    18. New approaches to treatment of schizophrenia by enhancing N-methyl-D-aspartate neurotransmission Guochuan Emil Tsai
    Subject index
    Author index.

  • Editor

    Jeffrey L. Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health
    Jeffrey Cummings is Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA and Director of the UCLA Alzheimer's Disease Center.

    Contributors

    Jeffrey L. Cummings, Antonio Culebras, Javier Borja, Julián García-Rafanell, Andrew D. Barreto, James C. Grotta, Sven E. Pålhagen, Esa Heinonen, Kelly E. Lyons, Rajesh Pahwa, G. Stennis Watson, Suzanne Craft, P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong, D. Garceau, E. Cittadini, P. J. Goadsby, Daniel Wynn, Catherine Meyer, Neil Allen, Dennis O'Brien, George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink, Roberta Tankanow, Robert B. Dick, Julia Sitterly, Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma, James P. Young, Hossein A. Khalili, Kamyar Keramatian, Erik Hessen, Morten I. Lossius, Ivar Reinvang, Leif Gjerstad, Paul B. Fitzgerald, F. Van Nieuwerburgh, D. Deforce, D. A. J. P. Denys, John P. O'Reardon, Karen E. Groff, Albert J. Stunkard, Kelly C. Allison, John H. Peloian, Joseph M. Pierre, Guochuan Emil Tsai

Sign In

Please sign in to access your account

Cancel

Not already registered? Create an account now. ×

Sorry, this resource is locked

Please register or sign in to request access. If you are having problems accessing these resources please email lecturers@cambridge.org

Register Sign in
Please note that this file is password protected. You will be asked to input your password on the next screen.

» Proceed

You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner www.ebooks.com. Please see the permission section of the www.ebooks.com catalogue page for details of the print & copy limits on our eBooks.

Continue ×

Continue ×

Continue ×

Find content that relates to you

Join us online

This site uses cookies to improve your experience. Read more Close

Are you sure you want to delete your account?

This cannot be undone.

Cancel

Thank you for your feedback which will help us improve our service.

If you requested a response, we will make sure to get back to you shortly.

×
Please fill in the required fields in your feedback submission.
×